Sana Biotechnology, Inc. Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent
Sana Biotechnology, Inc. (SANA) had Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent of $5.80 million as of 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Notes › Compensation Related Costs
us-gaap:DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent · last filed 2025-03-17
- 2024-12-31: Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent $5.80M.
- 2023-12-31: Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent $5.20M.
| Period end | Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent |
|---|---|
| 2024-12-31 | $5.80M 10-K · filed 2025-03-17 |
| 2023-12-31 | $5.20M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |